MedPath

NEUROCENTRIA, INC.

NEUROCENTRIA, INC. logo
🇺🇸United States
Ownership
Private
Established
2005-01-01
Employees
1
Market Cap
-
Website
http://www.neurocentria.com

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR with NRCT-202XR Compared to NRCT-202XR Alone in Subjects with Attention-Deficit/Hyperactivity Disorder

Phase 2
Recruiting
Conditions
ADHD
Interventions
Drug: NRCT-101SR, NRCT-202XR
First Posted Date
2024-11-04
Last Posted Date
2025-03-12
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
60
Registration Number
NCT06673368
Locations
🇺🇸

Accel Research Site-Maitland Clinical Research Unit, Maitland, Florida, United States

🇺🇸

iResearch Atlanta, Decatur, Georgia, United States

🇺🇸

CenExel iRS - iResearch Savannah, Savannah, Georgia, United States

and more 2 locations

Study to Evaluate NRCT-101SR in Pediatric Subjects with ADHD

Phase 2
Recruiting
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
First Posted Date
2024-01-22
Last Posted Date
2025-03-12
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
160
Registration Number
NCT06215144
Locations
🇺🇸

Advanced Research Center, Inc, Anaheim, California, United States

🇺🇸

Accel Research Sites - Lakeland Clinical Research Unit, Lakeland, Florida, United States

🇺🇸

Accel Research Sites Network - Maitland, Maitland, Florida, United States

and more 9 locations

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Phase 2
Completed
Conditions
ADHD
Interventions
Drug: Placebo
First Posted Date
2023-01-13
Last Posted Date
2025-06-03
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
223
Registration Number
NCT05683249
Locations
🇺🇸

Collaborative Neuroscience Network, Garden Grove, California, United States

🇺🇸

Accel Research Sites, Maitland, Florida, United States

🇺🇸

Miami Dade Medical Research Institute, Miami, Florida, United States

and more 5 locations

Comparison of MMFS Dosages in Older Adults

Phase 2
Completed
Conditions
Anxiety
Depression
Cognitive Impairment
Sleep Quality
Interventions
Dietary Supplement: High Dose MMFS-205-SR
Dietary Supplement: Placebo
Dietary Supplement: Low Dose MMFS-205-SR
First Posted Date
2018-07-26
Last Posted Date
2020-09-09
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
9
Registration Number
NCT03601169
Locations
🇺🇸

Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States

Efficacy and Safety of MMFS in Early AD

Phase 2
Completed
Conditions
Alzheimer Disease
Interventions
Dietary Supplement: Placebo
Dietary Supplement: MMFS-205-SR
First Posted Date
2018-05-22
Last Posted Date
2020-09-09
Lead Sponsor
Neurocentria, Inc.
Target Recruit Count
10
Registration Number
NCT03531684
Locations
🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath